1-2 of 2
Ksenia Titorenko, MS
Close
Save search
Sort by
Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Free
Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-137388
Published: 2020
Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Free
Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Surapol Issaragrisil, MD, Philipp Le Coutre, MD, Gabriel Etienne, MD PhD, Carla Boquimpani, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Viviane Dubruille, MD, Ian W. Flinn, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Ewa Medras, MD, Maria Zanichelli, MD, Israel Bendit, MD PhD, Manu Sondhi, MD PhD, Ksenia Titorenko, MS, Claire Nourry-Boulot, PhD, Paola Aimone, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2924.
https://doi.org/10.1182/blood-2019-128761
Published: 2019